BioPact's MGMR® Drug Delivery Technology Succeeds In Mitigating Side Effects Of Doxorubicin While Retaining Anti-Cancer Efficacy In Lymphoma And Metastasis Mouse Models

AUSTIN, Texas, June 14, 2017 /PRNewswire/ -- BioPact's nanodelivery technology produced in vivo evidence that the carbon nanotube-based drug delivery system, Medical-Grade MOLECULAR REBAR® (MGMR®), successfully treated two forms of cancer while reducing the side effects of the API in this study, Doxorubicin. The studies were conducted at Charles River Laboratories and utilized two orthotopic cancer models mimicking Raji B Lymphoma and Hepatic Metastasis.

In the Raji B study, the Doxorubicin arm was effective against the tumor however produced serious side effects. The high dosage required to combat the tumor's aggression elicited a ~20% weight loss in mice resulting in the death of >20% of the group.  In the MGMR+Doxorubicin arm, the combination remains as potent as Doxorubicin alone, however, with zero deaths and statistically significant improvements in weight loss. According to clinical observations of the mice there is a clear difference observed between the thin/lethargic Doxorubicin-treated arm and the normal body weight/active MGMR+Doxorubicin treated group.  Preliminary evidence suggests that a bone-targeted version of MGMR+Doxorubicin is more effective in diminishing the tumor burden while retaining health and body weight.

In the Liver Metastasis study, the Doxorubicin arm produced a ~50% drop in clinically observed indications of tumor burden (liver firmness, abdominal distention or discoloration) versus control animals.  MGMR+Doxorubicin enhanced the stability of the API in the liver and improved side effect profile vs. Doxorubicin alone.  When dosed with the combination of MGMR+Doxorubicin, the number of mice exhibiting the symptoms of cancer was decreased by 50% vs. Doxorubicin alone.  The study further suggests MGMR could decrease the amount of therapeutic required to elicit an effect through improved targeting and pharmacokinetics.

BioPact's VP of Business Development, Lainie Mulvanny, stated "These studies validate the efficacy of MGMR as a drug delivery platform and identifies key areas where the technology will add significant improvements to the industry.  MGMR continues to impress us; we look forward to sharing this data next week to potential collaborators at BIO." Paul Everill, BioPact's Director of Research and Development stated "These efficacy studies represent the culmination of almost three years of careful research, formulation, and development. We are very excited by the success of these recent data and the direction in which they drive our R+D platform."

SOURCE BioPact